Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

vs.MS

- PMLiVE

Genzyme continues MS drug rollout across EU

Lemtrada and Aubagio now available in Republic of Ireland

Biogen Idec building

Final NICE backing for Biogen Idec’s Tecfidera

Oral multiple sclerosis is cleared for NHS use in England

Biogen Idec building

FDA approves Biogen Idec’s long-acting MS therapy

Plegridy gets US nod just weeks after EU approval

- PMLiVE

Cancer Research UK calls for accuracy on Wikipedia

Appeals to healthcare community to keep online information up to date

- PMLiVE

Rebif hit again as competition bites

Merck Serono’s MS drug continues its struggle for sales in the US and Europe

MS market set to grow 4% annually

Predictedto reach $20bn by 2023 partly due to Plegridy and ocrelizumab launches

Fishawack buys UK med comms agency Facilitate

Dealis the Fishawack Group's third in just over a year

- PMLiVE

ICC Lowe launches new digital offerings

Range includes sales rep, education, social data and content curation tools

- PMLiVE

Amgen launches bowel cancer web portal in Spain

Aims to help healthcare professionals understand about personalised medicine

Biogen Idec building

Plegridy approval underlines Biogen Idec’s dominance in MS

And Tecfidera boosts pharma company’s second quarter financial results

- PMLiVE

Social media – part of the routine

The necessity of a social media engagement strategy for pharma companies

Understanding the post-digital world

Online marketing increasingly effective for pharma

comScore report shows branded sites can impact medicine usage

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links